No quarterly revenue total was found in REVELATION BIOSCIENCES, INC.'s SEC filings.
Revelation Biosciences, Inc. (REVB) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$2.4 million. As of Sep 30, 2026 it held $9.1 million in cash and investments and $805,399 in total debt.
Revenue
—
Net income
$-3.32M
-73.8% vs year-ago quarter
Operating cash flow
$-2.36M
-48.6% vs year-ago quarter
Free cash flow
$-2.36M
+9.1% vs prior quarter
EPS
$-5.92
+88.0% vs year-ago quarter
Dividend per share
None
Shares outstanding
683,442
-88.5% vs year-ago quarter
Net cash
$8.32M
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REVB (Nasdaq), REVBW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1810560
- Former names
- Petra Acquisition Inc. (until Jan 11, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$3.4M | -$3.7M | -$3.1M | -$2.6M | -$1.9M |
| Net income | -$3.3M | -$3.3M | -$3.0M | -$2.5M | -$1.9M |
| Diluted EPS | -$5.92 | -$0.87 | -$2.71 | -$1.08 | -$49.51 |
| Operating cash flow | -$2.4M | -$2.6M | -$3.2M | -$2.0M | -$1.6M |
| Free cash flow | -$2.4M | -$2.6M | -$3.3M | — | — |
| Total assets | $10.0M | $12.5M | $15.0M | $11.6M | $12.9M |
| Total liabilities | $2.8M | $2.4M | $2.1M | $2.7M | $1.9M |
| Stockholders' equity | $7.2M | $10.1M | $13.0M | $8.9M | $11.0M |
| Cash and investments | $9.1M | $11.5M | $14.1M | $10.7M | $12.7M |
| Total debt | $805,399 | $739,916 | $759,044 | $746,784 | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change
|
Aug 19, 2026 | Aug 17, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Material agreement, Change to shareholder rights, Bylaw or fiscal year change, Regulation FD disclosure
|
Jul 13, 2026 | Jul 10, 2026 |
All 389 Revelation Biosciences, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.